CN104352718A - Medicine for treating osteoporosis and preparation method thereof - Google Patents
Medicine for treating osteoporosis and preparation method thereof Download PDFInfo
- Publication number
- CN104352718A CN104352718A CN201410697514.7A CN201410697514A CN104352718A CN 104352718 A CN104352718 A CN 104352718A CN 201410697514 A CN201410697514 A CN 201410697514A CN 104352718 A CN104352718 A CN 104352718A
- Authority
- CN
- China
- Prior art keywords
- parts
- medicine
- preparation
- osteoporosis
- rhizoma dioscoreae
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/487—Psoralea
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/32—Bones; Osteocytes; Osteoblasts; Tendons; Tenocytes; Teeth; Odontoblasts; Cartilage; Chondrocytes; Synovial membrane
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/21—Amaranthaceae (Amaranth family), e.g. pigweed, rockwort or globe amaranth
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/39—Convolvulaceae (Morning-glory family), e.g. bindweed
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/46—Eucommiaceae (Eucommia family), e.g. hardy rubber tree
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/64—Orobanchaceae (Broom-rape family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/80—Scrophulariaceae (Figwort family)
- A61K36/804—Rehmannia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/894—Dioscoreaceae (Yam family)
- A61K36/8945—Dioscorea, e.g. yam, Chinese yam or water yam
Abstract
The invention provides a medicine for treating osteoporosis and a preparation method thereof. The medicine for treating the osteoporosis comprises the following raw materials in parts by weight: 6-10 parts of fructus psoraleae, 9-15 parts of prepared rehmannia root, 5-10 parts of radix cyathulae, 3-6 parts of deer-horn glue, 6-12 parts of semen cuscutae, 6-10 parts of herba cistanche, 6-10 parts of eucommia ulmoides, 9-15 parts of rhizoma dioscoreae hypoglaucae and 15-30 parts of Chinese yam. According to the preparation method of the medicine for treating the osteoporosis, effective components of the medicine are fully released by superfine grinding of the traditional Chinese medicines. The medicine for treating the osteoporosis and the preparation method thereof, provided by the invention, can increase the utilization rate of the raw traditional Chinese medicines; the medicine is convenient to store and take and has a remarkable curative effect on senile osteoporosis and postmenopausal osteoporosis.
Description
Technical field
The present invention relates to the field of Chinese medicines, be specifically related to one and treat osteoporotic medicine and preparation method thereof.
Background technology
Osteoporosis be a kind of with Low BMD and osseous tissue Microstructure Fracture for feature, cause skeletal fragility to increase and the systemic disease of fracture easily occur.Along with the aging of social population, osteoporosis sickness rate is more and more higher, and based on postmenopausal women, becomes the general bone metabolism disease that current old women is common, is also the major reason of elderly woman fracture.Current existing treatment osteoporotic Chinese medicine Chinese crude drug utilization rate is not high, and prescription is complicated, and function is simple, and curative effect is clear and definite not, and take and store convenient not.
Summary of the invention
The object of this invention is to provide one and can improve Chinese crude drug utilization rate, be convenient to store and take, to senile osteoporosis, women's osteosporosis after menopause disease medicine having therapeutic efficiency and preparation method thereof.
A kind of raw material for the treatment of osteoporotic medicine and comprising following weight portion of the present invention: Fructus Psoraleae 6-10 part, Radix Rehmanniae Preparata 9-15 part, Radix Cyathulae 5-10 part, Colla cornus cervi 3-6 part, Semen Cuscutae 6-12 part, Herba Cistanches 6-10 part, Cortex Eucommiae 6-10 part, Rhizoma Dioscoreae Hypoglaucae 9-15 part, Rhizoma Dioscoreae 15-30 part.
A kind of preparation method for the treatment of osteoporotic medicine of the present invention, by Fructus Psoraleae 6-10 part, Radix Rehmanniae Preparata 9-15 part, Radix Cyathulae 5-10 part, Colla cornus cervi 3-6 part, Semen Cuscutae 6-12 part, Herba Cistanches 6-10 part, Cortex Eucommiae 6-10 part, Rhizoma Dioscoreae Hypoglaucae 9-15 part, Rhizoma Dioscoreae 15-30 part, after drying, pulverize, be processed into 20-40 order coarse powder; Then adopt the vibrations of micronizing method to pulverize, mill feed size coarse powder 20-40 order, moisture is less than 8%, pulverizes temperature and controls at 0 DEG C-15 DEG C, pulverize after 12-15 minute, obtain micropowders.
Wherein, described micropowders is packed, makes electuary; After described micropowders is decocted purification, make water preparation; After described micropowders vacuum drying, make capsule; After being boiled by described micropowders, make unguentum.
Medicine of the present invention take Fructus Psoraleae as monarch drug, Fructus Psoraleae has effect of kidney warming and yang invigorating, improving inspiration by invigorating kidney-QI, antidiarrheal, ancient Chinese medicine doctor is widely used in it in the prescription of all kinds of reinforcing the kidney to strengthen the bone, Fructus Psoraleae contains psoralen, isopsoralen, Coryfolin, corylin, Corylifolinin various active material, can osteoblastic propagation be promoted, have the effect of osteoporosis.Radix Rehmanniae Preparata has fills out bone marrow, longue meat, promoting generation of vital essence and blood, tonifying five ZANG-organs, sharp knowledge, black beard and hair, the effect of promoting blood circulation.Experiment shows that Radix Rehmanniae Preparata can suppress bone resorption, delays bone loss, has inhibitory action to osteoporosis.Colla cornus cervi temperature compensation Liver and kidney, beneficial intensive culture blood, the generation to bone of the colloid be rich in, calcium phosphate, calcium carbonate, magnesium phosphate, aminoacid provides material base.Two medicines are ministerial drug altogether.Distinguishing of Rhizoma Dioscoreae Hypoglaucae essence can be changed into QI, Cortex Eucommiae the kidney invigorating is with the strong waist of strong knee joint, and Herba Cistanches is moisturized and added essence.The dirty replenishing essence room of Herba cuscutae the kidney invigorating, the dirty benefit of Colla cornus cervi warming the kidney is congenital, and The spleen and stomach provide the material basis of the acquired, it is extremely important that good taste effectively become absorption to medicine, therefore mend the day after tomorrow with Rhizoma Dioscoreae, and these a few herbs are adjuvant drug altogether, Radix Cyathulae walks and can mend, and property is apt to descending, therefore enters Liver and kidney for making medicine.Make to fill in kidney liquid, then the flourish bone pool of the self-sustaining and muscle of essence and blood.Medicine of the present invention is correlated mutually by " monarch, minister, help, make " various kinds of drug, improves the synergism of Chinese medicine in formula, has transferred the usefulness of medicine, enhance the effect of Drug therapy osteoporosis of the present invention.
The preparation method of the osteoporotic medicine for the treatment of of the present invention is passed through Chinese medicine micronized pulverization, the active ingredient of medicine is fully discharged, thus make the effective ingredient-use rate of the ultramicro decoction piece of 1g be equivalent to the 5g of Chinese medicine material, treat osteoporotic drug effect and also significantly improve.
Detailed description of the invention
Below in conjunction with specific embodiment, the present invention is described in further detail, and following examples are explanation of the invention, and the present invention is not limited to following examples.
Embodiment 1
One treats osteoporotic medicine, comprises the raw material of following weight portion: Fructus Psoraleae 6 parts, Radix Rehmanniae Preparata 9 parts, Radix Cyathulae 5 parts, Colla cornus cervi 3 parts, Semen Cuscutae 6 parts, Herba Cistanches 6 parts, the Cortex Eucommiae 6 parts, Rhizoma Dioscoreae Hypoglaucae 9 parts, Rhizoma Dioscoreae 15 parts.
The raw material of selected above-mentioned weight portion, after drying, pulverizes, is processed into 20-40 order coarse powder; Then adopt the vibrations of micronizing method to pulverize, mill feed size coarse powder 20-40 order, moisture is less than 8%, pulverizes temperature and controls at 0 DEG C-15 DEG C, pulverize after 12-15 minute, obtain micropowders; Micropowders is packed, makes electuary.
Embodiment 2
One treats osteoporotic medicine, comprises the raw material of following weight portion: Fructus Psoraleae 10 parts, Radix Rehmanniae Preparata 15 parts, Radix Cyathulae 10 parts, Colla cornus cervi 6 parts, Semen Cuscutae 12 parts, Herba Cistanches 10 parts, the Cortex Eucommiae 10 parts, Rhizoma Dioscoreae Hypoglaucae 15 parts, Rhizoma Dioscoreae 30 parts.
The raw material of selected above-mentioned weight portion, after drying, pulverizes, is processed into 20-40 order coarse powder; Then adopt the vibrations of micronizing method to pulverize, mill feed size coarse powder 20-40 order, moisture is less than 8%, pulverizes temperature and controls at 0 DEG C-15 DEG C, pulverize after 12-15 minute, obtain micropowders; After micropowders vacuum drying, make capsule.
Embodiment 3
One treats osteoporotic medicine, comprises the raw material of following weight portion: Fructus Psoraleae 6 parts, Radix Rehmanniae Preparata 10 parts, Radix Cyathulae 5 parts, Colla cornus cervi 4 parts, Semen Cuscutae 10 parts, Herba Cistanches 8 parts, the Cortex Eucommiae 6 parts, Rhizoma Dioscoreae Hypoglaucae 9 parts, Rhizoma Dioscoreae 20 parts.
The raw material of selected above-mentioned weight portion, after drying, pulverizes, is processed into 20-40 order coarse powder; Then adopt the vibrations of micronizing method to pulverize, mill feed size coarse powder 20-40 order, moisture is less than 8%, pulverizes temperature and controls at 0 DEG C-15 DEG C, pulverize after 12-15 minute, obtain micropowders; After being boiled by micropowders, make unguentum.
The medicine obtained embodiment 1 result of doing experiment is as follows:
In zoopery: adopt castration method back excision bilateral ovaries, set up castrated rats model, with medicine of the present invention to rat oral gavage, rear use x-ray borne densitometers, adopts toy bone densitometry software, measures rat right hind leg femur BMD; Use bone alkaline phosphatase euzymelinked immunosorbent assay (ELISA), calculate the content of bone-specific alkaline phosphatase (BALP); TRAP 5b immunity enzyme-linked method is used to detect rat blood serum Tartrate resistant acid phosphatase (serum T RACPb5) level;
Table 1 respectively organizes femur BMD on the right side of rat
Note:
1.p < 0.05 is compared with blank group between group;
2.compare the equal < 0.05 of P value with model group between group;
3.sham operated rats compares P < 0.05 with Chinese drug-treated group (ultra micro Buddha's warrior attendant group), positive controls (GUSHUKANG KELI group);
4.chinese drug-treated group compares the equal > 0.05 of P value with positive controls.
Table 2 each group rat bone specific alkaline phosphatase (BALP) (g:
± s; N=10)
Note:
1.p < 0.05 is compared with blank group between group;
2.compare the equal < 0.05 of P value with model group between group;
3.sham operated rats compares P < 0.05 with Chinese drug-treated group (ultra micro Buddha's warrior attendant group), positive controls (GUSHUKANG KELI group);
4.chinese drug-treated group compares the equal > 0.05 of P value with positive controls.
Table 3 each group rat blood serum Tartrate resistant acid phosphatase (serum T RACP5b) (g:
± s; N=10)
Note:
1.p < 0.05 is compared with blank group between group;
2.compare the equal < 0.05 of P value with model group between group;
3.sham operated rats compares P < 0.05 with Chinese drug-treated group (ultra micro Buddha's warrior attendant group), positive controls (GUSHUKANG KELI group);
4.chinese drug-treated group compares the equal > 0.05 of P value with positive controls.
Result shows: Chinese drug-treated group and positive controls all have the effect stoping castrated rats BDM to reduce, and reduces BALP, TRACP5b level in serum.Medicine of the present invention has the effect obviously stoping the reduction of castrated rats bone density, reduce bone-specific alkaline phosphatase (BALP) and serum Tartrate resistant acid phosphatase (serum T RACP5b) content in Ovariectomized Rat Serum.
We have carried out clinical and experimental study in Hunan Affiliated Hospital of Chinese medicine study institute to old matter osteoporosis patient, employing demixing zone group is random, parallel positive drug contrasts, clinical research methods is observed in double blinding, has formulated clinical trial protocol with reference to " People's Republic of China's standard disease of tcm is diagnosed and criterion of therapeutical effect " " guideline of clinical investigations of new Chinese medicine treatment osteoporosis ".Carry out clinical experiment for 100 routine Aged Patients with Osteoporosis, give qualified patients with osteoporosis every day 2 times, each 2 bags of superfine powder, boiled water is taken after mixing it with water, wherein clinical cure 36 example, effective 44 examples, effective 15 examples, invalid 5 examples, total effective rate 95%.Clinical experiment is carried out for 80 routine postmenopausal osteoporosis patients, gives qualified patients with osteoporosis every day 2 times, each 1 bag of superfine powder, boiled water is taken after mixing it with water, wherein clinical cure 32 example, effective 38 examples, effective 7 examples, invalid 4 examples, total effective rate 96.2%.
Medicine of the present invention, to senile osteoporosis, women's osteosporosis after menopause disease patient all has significant curative effect, curative effect is determined, does not occur any adverse side effect.
Claims (6)
1. treat an osteoporotic medicine, it is characterized in that the raw material comprising following weight portion: Fructus Psoraleae 6-10 part, Radix Rehmanniae Preparata 9-15 part, Radix Cyathulae 5-10 part, Colla cornus cervi 3-6 part, Semen Cuscutae 6-12 part, Herba Cistanches 6-10 part, Cortex Eucommiae 6-10 part, Rhizoma Dioscoreae Hypoglaucae 9-15 part, Rhizoma Dioscoreae 15-30 part.
2. treat the preparation method of osteoporotic medicine for one kind, it is characterized in that: by Fructus Psoraleae 6-10 part, Radix Rehmanniae Preparata 9-15 part, Radix Cyathulae 5-10 part, Colla cornus cervi 3-6 part, Semen Cuscutae 6-12 part, Herba Cistanches 6-10 part, Cortex Eucommiae 6-10 part, Rhizoma Dioscoreae Hypoglaucae 9-15 part, Rhizoma Dioscoreae 15-30 part, after drying, pulverize, be processed into 20-40 order coarse powder; Then adopt the vibrations of micronizing method to pulverize, mill feed size coarse powder 20-40 order, moisture is less than 8%, pulverizes temperature and controls at 0 DEG C-15 DEG C, pulverize after 12-15 minute, obtain micropowders.
3. the preparation method of the osteoporotic medicine for the treatment of according to claim 2, is characterized in that: packed by described micropowders, make electuary.
4. the preparation method of the osteoporotic medicine for the treatment of according to claim 2, is characterized in that: after described micropowders is decocted purification, make water preparation.
5. the preparation method of the osteoporotic medicine for the treatment of according to claim 2, is characterized in that: after described micropowders vacuum drying, make capsule.
6. the preparation method of the osteoporotic medicine for the treatment of according to claim 2, is characterized in that: after being boiled by described micropowders, make unguentum.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410697514.7A CN104352718A (en) | 2014-11-26 | 2014-11-26 | Medicine for treating osteoporosis and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410697514.7A CN104352718A (en) | 2014-11-26 | 2014-11-26 | Medicine for treating osteoporosis and preparation method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN104352718A true CN104352718A (en) | 2015-02-18 |
Family
ID=52520091
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201410697514.7A Pending CN104352718A (en) | 2014-11-26 | 2014-11-26 | Medicine for treating osteoporosis and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN104352718A (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105456524A (en) * | 2015-12-14 | 2016-04-06 | 苏州枫灵医药科技有限公司 | Medicinal preparation for treating osteoporosis |
| CN113713067A (en) * | 2021-08-25 | 2021-11-30 | 广州中医药大学第三附属医院(广州中医药大学第三临床医学院、广州中医药大学附属骨伤科医院、广州中医药大学骨伤科研究所) | Traditional Chinese medicine composition for preventing and treating sarcopenia osteoporosis and preparation method thereof |
| CN114470174A (en) * | 2022-03-09 | 2022-05-13 | 扬州大学 | Composition for preventing and treating osteoporosis |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1931280A (en) * | 2006-09-24 | 2007-03-21 | 四川美大康药业股份有限公司 | Medicine for treating osteoporosis and its prepn process |
| CN103417763A (en) * | 2013-07-16 | 2013-12-04 | 李青平 | Medicinal composition for treating osteoporosis and preparation method and application of medicinal composition |
| CN103920000A (en) * | 2014-03-26 | 2014-07-16 | 泸州市中医医院 | Traditional Chinese medicine composition for treating osteoporosis and preparation method thereof |
| CN104107307A (en) * | 2014-07-09 | 2014-10-22 | 逄海东 | Medicinal composition for treating osteoporosis |
-
2014
- 2014-11-26 CN CN201410697514.7A patent/CN104352718A/en active Pending
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1931280A (en) * | 2006-09-24 | 2007-03-21 | 四川美大康药业股份有限公司 | Medicine for treating osteoporosis and its prepn process |
| CN103417763A (en) * | 2013-07-16 | 2013-12-04 | 李青平 | Medicinal composition for treating osteoporosis and preparation method and application of medicinal composition |
| CN103920000A (en) * | 2014-03-26 | 2014-07-16 | 泸州市中医医院 | Traditional Chinese medicine composition for treating osteoporosis and preparation method thereof |
| CN104107307A (en) * | 2014-07-09 | 2014-10-22 | 逄海东 | Medicinal composition for treating osteoporosis |
Non-Patent Citations (1)
| Title |
|---|
| 匡建军 等: "超微金刚治疗绝经后骨质疏松症60例", 《湖南中医杂志》 * |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105456524A (en) * | 2015-12-14 | 2016-04-06 | 苏州枫灵医药科技有限公司 | Medicinal preparation for treating osteoporosis |
| CN113713067A (en) * | 2021-08-25 | 2021-11-30 | 广州中医药大学第三附属医院(广州中医药大学第三临床医学院、广州中医药大学附属骨伤科医院、广州中医药大学骨伤科研究所) | Traditional Chinese medicine composition for preventing and treating sarcopenia osteoporosis and preparation method thereof |
| CN113713067B (en) * | 2021-08-25 | 2023-03-10 | 广州中医药大学第三附属医院(广州中医药大学第三临床医学院、广州中医药大学附属骨伤科医院、广州中医药大学骨伤科研究所) | Traditional Chinese medicine composition for preventing and treating sarcopenia osteoporosis and preparation method thereof |
| CN114470174A (en) * | 2022-03-09 | 2022-05-13 | 扬州大学 | Composition for preventing and treating osteoporosis |
| CN114470174B (en) * | 2022-03-09 | 2023-11-10 | 扬州大学 | Composition for preventing and treating osteoporosis |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102526326B (en) | Traditional Chinese medicine for treating postmenopausal osteoporosis and preparation method thereof | |
| CN1319569C (en) | Chinese medicine preparation for treating osteoporosis and fracture and preparation process thereof | |
| CN104352718A (en) | Medicine for treating osteoporosis and preparation method thereof | |
| CN104524335A (en) | Pill for conditioning female endocrine disorders and preparation method of pill | |
| CN102327436A (en) | Traditional Chinese medicine composition for treating edema during menstruation | |
| CN103550383A (en) | Traditional Chinese medicine composition for treating cervical spondylosis | |
| CN103191315B (en) | Traditional Chinese medicine for treating postmenopausal osteoporosis | |
| CN106075347A (en) | One treats cervical and lumbar diseases and arthritic external application Chinese medicine unguentum | |
| CN105106919A (en) | Healthcare medicinal liquor as well as preparation method and application | |
| CN101455755B (en) | Yang-strengthening preparation for treating yang-insufficiency type impotence and preparation method thereof | |
| CN104352907A (en) | Traditional Chinese medicine composition for treating chronic gouty arthritis | |
| CN106215110A (en) | A kind of bone knitting powder Chinese medicine composition | |
| CN105169089A (en) | Traditional Chinese medicine pill for treating headache during menstruation and preparing method of traditional Chinese medicine pill | |
| CN105106363A (en) | Traditional Chinese medicine for promoting healing of bone fracture | |
| CN102283960B (en) | Traditional Chinese medicine composition for preventing and treating osteoporosis and preparation method thereof | |
| CN103285233B (en) | Pharmaceutical composition used together with nursing for treating postmenopausal osteoporosis | |
| CN104547989A (en) | Tibetan paste for treating spondylodynia and using method thereof | |
| CN105477216A (en) | Drug for treating gray hair | |
| CN103690644A (en) | Traditional Chinese medicine preparation for promoting fracture rehabilitation | |
| CN102406753A (en) | Chinese medicinal composition for treating Bi syndrome | |
| CN1733063A (en) | Orally medicine for treating vitiligo and production method thereof | |
| CN104399022A (en) | Traditional Chinese medicine composition for treating osteoporosis and applications thereof | |
| CN105194309A (en) | Externally used paste for treating osteoporosis and preparation method thereof | |
| CN106215108A (en) | A kind of bone knitting powder medicated powder | |
| CN106215111A (en) | A kind of bone knitting powder Chinese medicine preparation |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20150218 |
|
| RJ01 | Rejection of invention patent application after publication |